03 May 2020 : Clinical Research
Inhibition of MiR-10b Restrains the Migration and Epithelial-Mesenchymal Transition of Lung Cells by Targeting LATS2 via TAZ Pathway
Yunlong Yang1ABCE*, Jianzhong Wang1BCDFDOI: 10.12659/MSM.920275
Med Sci Monit 2020; 26:e920275
Abstract
BACKGROUND: MiR-10b can promote the growth of lung cancer cells. LATS2 is reported to regulate lung cancer cell proliferation. We aimed to study the relationship between miR-10b and LATS2 in lung cancer.
MATERIAL AND METHODS: MiR-10b and LATS2 in lung cancer tissues and cells were measured via real-time polymerase chain reaction (RT-PCR) and western blotting. Luciferase reporter assay and mimic transfection were performed to study relation between miR-10b and LATS2. MiR-10b inhibitor was transfected to downregulate miR-10b expression and LATS2 was further downregulated. Then, the proliferation, apoptosis, migration, and invasion capacity of lung cancer cells were measured, respectively. Lung cancer cells stably transfected with LATS2 and TAZ plasmids were constructed as usual, and the effect of LATS2 overexpression on epithelial-mesenchymal transition (EMT) was determined.
RESULTS: MiR-10b was upregulated and LATS2 was significantly downregulated in lung cancer. Inhibition of miR-10b restrained the growth of lung cancer cells and accelerated the apoptosis of lung cancer cells. LATS2 is directly bound by miR-10b and silence of LATS2 reversed its inhibitory and promotive effects. Overexpression of LATS2 inhibited the EMT of lung cancer cells by inhibiting the TAZ pathway.
CONCLUSIONS: MiR-10b was upregulated in lung cancer. Inhibition of miR-10b could restrain the development of lung cancer by increasing LATS2 expression via TAZ.
Keywords: enoxaparin, Receptors, Thyrotropin, Protein Serine-Threonine Kinases, Trans-Activators, Transcriptional Coactivator with PDZ-Binding Motif Proteins, Transfection, Tumor Suppressor Proteins
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952